key: cord-0702077-b6ip95jo
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
date: 2022-03-09
journal: ESC Heart Fail
DOI: 10.1002/ehf2.13868
sha: 27aabb5bbb8202e6bc8d91a61bd9b6a840a9f5d6
doc_id: 702077
cord_uid: b6ip95jo

nan

We would like to share ideas on the publication 'Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report'. 1 Naghashzadeh et al. concluded that 'endomyocardial biopsy proved lymphocytic myocarditis such that the patient was successfully treated with immunosuppressive and guideline-directed medical treatment'. 1 We agree that the COVID-19 vaccination has the potential to cause side effects. The patient in this case developed a heart condition, 1 which might or could not be related to COVID-19 vaccine. It's difficult to draw a definitive judgement because there's no information on the patient's immunological condition prior to immunization. A concomitant medical complication in a vaccination recipient is possible. Dengue fever, for example, is a potentially concomitant medical issue that can cause myocarditis in COVID-19 vaccine recipients. 2 Finally, we agree that the recommended immunosuppression is a good choice for patient management and that it could be used whether or not the COVID-19 vaccine is the cause of myocarditis. 

Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report. ESC Heart Fail 2022 Online ahead of print

Dengue after COVID-19 vaccination: possible and might be missed